STOCK TITAN

Genetron Holdings Ltd - GTH STOCK NEWS

Welcome to our dedicated news page for Genetron Holdings (Ticker: GTH), a resource for investors and traders seeking the latest updates and insights on Genetron Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genetron Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genetron Holdings's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.4%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.64%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
Genetron Holdings Ltd

Nasdaq:GTH

GTH Rankings

GTH Stock Data

127.29M
214.77M
6.82%
12.51%
0.07%
Medical Laboratories
Health Care and Social Assistance
Link
China
Beijing

About GTH

genetron holdings limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. the company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as hccscreen, a proprietary assay for the early screening of liver cancer. it also provides in-vitro diagnostics products, including 8-gene lung cancer assay, an ivd assay product based on semiconductor sequencing to detect lung cancer; genetron 3d biochip reading instrument; idh1/tert gene assays for glioma; genetron s5, a semiconductor sequencer used in the field of gene detection; and genetron s2000 that enables gene panel sequencing. in addition, the company develops ctdna lung cancer assay for mutations in the epidermal growth factor receptor gene. it also offers development services in the areas of genomics research and clinical development in collabor